(Q36651643)

15 August 2017

1 reference

title

Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? (English)

1 reference

15 August 2017

Morten A Karsdal

1

1 reference

15 August 2017

Per Qvist

series ordinal

2

1 reference

15 August 2017

Claus Christiansen

series ordinal

3

1 reference

15 August 2017

László B Tankó

series ordinal

4

1 reference

15 August 2017

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

66

1 reference

15 August 2017

15

1 reference

15 August 2017

1909-1918

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666150-00002

15 August 2017

0 references

cites work

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

1 reference

12 December 2020

Bisphosphonates--a word of caution.

1 reference

12 December 2020

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

12 December 2020

Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update

1 reference

12 December 2020

Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk

1 reference

12 December 2020

Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses

1 reference

12 December 2020

Bisphosphonates and osteonecrosis of the jaw

1 reference

12 December 2020

Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man

1 reference

12 December 2020

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

1 reference

12 December 2020

Changes in bone density and turnover after alendronate or estrogen withdrawal.

1 reference

12 December 2020

Therapeutic approaches to bone diseases

1 reference

12 December 2020

Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group

1 reference

12 December 2020

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice

1 reference

12 December 2020

Pyknodysostosis--a report of two cases with a brief review of the literature

1 reference

12 December 2020

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

12 December 2020

Bone matters: are density increases necessary to reduce fracture risk?

1 reference

12 December 2020

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

1 reference

12 December 2020

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

12 December 2020

Osteoclast precursors, RANKL/RANK, and immunology

1 reference

12 December 2020

Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase

1 reference

12 December 2020

Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density

1 reference

12 December 2020

Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene

1 reference

12 December 2020

Comparison of Serum and Urine Assays for Biochemical Markers of Bone Resorption in Postmenopausal Women with and without Hormone Replacement Therapy and in Men

1 reference

12 December 2020

Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength

1 reference

12 December 2020

Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease

1 reference

12 December 2020

Role of osteoblasts in hormonal control of bone resorption—A hypothesis

1 reference

12 December 2020

Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study

1 reference

12 December 2020

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial

1 reference

12 December 2020

Do Markers of Bone Resorption Add to Bone Mineral Density and Ultrasonographic Heel Measurement for the Prediction of Hip Fracture in Elderly Women? The EPIDOS Prospective Study

1 reference

12 December 2020

Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs

1 reference

12 December 2020

Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study.

1 reference

12 December 2020

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

1 reference

12 December 2020

Pseudo-avascular necrosis of the hips in a sporadic case of osteopetrosis

1 reference

12 December 2020

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

1 reference

12 December 2020

Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate

1 reference

12 December 2020

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

1 reference

12 December 2020

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

1 reference

12 December 2020

The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants

1 reference

12 December 2020

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

12 December 2020

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

12 December 2020

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

12 December 2020

The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation

1 reference

12 December 2020

Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.

1 reference

12 December 2020

Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.

1 reference

12 December 2020

Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?

1 reference

12 December 2020

Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis

1 reference

12 December 2020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

12 December 2020

Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse

1 reference

12 December 2020

Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal.

1 reference

12 December 2020

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

1 reference

12 December 2020

The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.

1 reference

12 December 2020

Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis

1 reference

12 December 2020

Hormones in the coupling of bone resorption and formation

1 reference

12 December 2020

Denosumab in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study1

1 reference

12 December 2020

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

1 reference

12 December 2020

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

12 December 2020

Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone

1 reference

12 December 2020

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Severe malignant osteopetrosis caused by a GL gene mutation.

1 reference

12 December 2020

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

1 reference

12 December 2020

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

1 reference

12 December 2020

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

1 reference

12 December 2020

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

12 December 2020

Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage

1 reference

12 December 2020

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

1 reference

12 December 2020

Age and bone mass as predictors of fracture in a prospective study

1 reference

12 December 2020

Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor.

1 reference

12 December 2020

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

1 reference

12 December 2020

10.2165/00003495-200666150-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference